MovDisordV3, Main, Exploration, bibRecord, 003766

Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

Identifieur interne : 003766 ( Main/Exploration ); précédent : 003765; suivant : 003767

Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

Auteurs : Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann [États-Unis] ; Michael S. Okun [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-01.

RBID : ISTEX:FE55B88FED2132D9D61F9ED5D4B0AF6ECD4C5EAE

Descripteurs français

Pascal (Inist)
- Antipsychotique, Clozapine, Parkinson maladie, Psychose, Quétiapine, Rebond, Système nerveux pathologie.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Antipsychotic, Antipsychotic Agents (adverse effects), Brief Psychiatric Rating Scale, Clozapine, Clozapine (adverse effects), Dibenzothiazepines (adverse effects), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Tolerance, Female, Humans, Male, Nervous system diseases, Parkinson Disease (complications), Parkinson disease, Parkinson, psychosis, Prospective Studies, Psychosis, Psychotic Disorders (complications), Psychotic Disorders (drug therapy), Quetiapine, Rebound, Recurrence, Time Factors, atypical antipsychotic, clozapine, discontinuation, quetiapine.
MESH :
- chemical , adverse effects : Antipsychotic Agents, Clozapine, Dibenzothiazepines.
- complications : Parkinson Disease, Psychotic Disorders.
- drug therapy : Psychotic Disorders.
- Aged, Aged, 80 and over, Brief Psychiatric Rating Scale, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Tolerance, Female, Humans, Male, Prospective Studies, Recurrence, Time Factors.

Abstract

To determine whether psychiatrically stable patients with a history of drug‐induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on‐going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the “rebound psychosis” was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/FE55B88FED2132D9D61F9ED5D4B0AF6ECD4C5EAE/fulltext/pdf

DOI: 10.1002/mds.20260

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
</author>
<author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
</author>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FE55B88FED2132D9D61F9ED5D4B0AF6ECD4C5EAE</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20260</idno>
<idno type="url">https://api.istex.fr/document/FE55B88FED2132D9D61F9ED5D4B0AF6ECD4C5EAE/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003689</idno>
<idno type="wicri:Area/Istex/Curation">003689</idno>
<idno type="wicri:Area/Istex/Checkpoint">002173</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Fernandez H:rebound:psychosis:effect</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15390047</idno>
<idno type="wicri:Area/PubMed/Corpus">003266</idno>
<idno type="wicri:Area/PubMed/Curation">003266</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F85</idno>
<idno type="wicri:Area/Ncbi/Merge">001022</idno>
<idno type="wicri:Area/Ncbi/Curation">001022</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001022</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Fernandez H:rebound:psychosis:effect</idno>
<idno type="wicri:Area/Main/Merge">004E50</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0173244</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F45</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D76</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D33</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Fernandez H:rebound:psychosis:effect</idno>
<idno type="wicri:Area/Main/Merge">005211</idno>
<idno type="wicri:Area/Main/Curation">003766</idno>
<idno type="wicri:Area/Main/Exploration">003766</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Florida/McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-01">2005-01</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="104">104</biblScope>
<biblScope unit="page" to="105">105</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">FE55B88FED2132D9D61F9ED5D4B0AF6ECD4C5EAE</idno>
<idno type="DOI">10.1002/mds.20260</idno>
<idno type="ArticleID">MDS20260</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Brief Psychiatric Rating Scale</term>
<term>Clozapine</term>
<term>Clozapine (adverse effects)</term>
<term>Dibenzothiazepines (adverse effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug Tolerance</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Parkinson, psychosis</term>
<term>Prospective Studies</term>
<term>Psychosis</term>
<term>Psychotic Disorders (complications)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Quetiapine</term>
<term>Rebound</term>
<term>Recurrence</term>
<term>Time Factors</term>
<term>atypical antipsychotic</term>
<term>clozapine</term>
<term>discontinuation</term>
<term>quetiapine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Clozapine</term>
<term>Dibenzothiazepines</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Brief Psychiatric Rating Scale</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug Tolerance</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Prospective Studies</term>
<term>Recurrence</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term>
<term>Clozapine</term>
<term>Parkinson maladie</term>
<term>Psychose</term>
<term>Quétiapine</term>
<term>Rebond</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine whether psychiatrically stable patients with a history of drug‐induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on‐going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the “rebound psychosis” was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Rhode Island</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
</region>
<name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S." last="Okun">Michael S. Okun</name>
<name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E." last="Trieschmann">Martha E. Trieschmann</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003766 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003766 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:FE55B88FED2132D9D61F9ED5D4B0AF6ECD4C5EAE
   |texte=   Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.